People with Stroke More Likely to Have Multimorbidities, Polypharmacy
the Neurology Advisor take:
People with multimorbidities and polypharmacy, especially those who have been diagnosed with stroke, are at a high risk of experiencing treatment burden, according to a large cross-sectional study published in BMC Medicine.
The affects of multimorbidity are often overlooked by healthcare professionals despite its prevalence in people with chronic illness such as stroke. Polypharmacy often accompanies multimorbidities and only adds to a person’s treatment burden with risk for adverse drug reactions.
Researchers studied 1,424,378 subjects in Scotland in order to evaluate the presence of multimorbidities and polypharmacy. Of the participants, which were 18 years and over, 2.5%, or 35,690 people had a diagnosis of stroke. Among the 39 other comorbidities examined, 35 were much more common in those with stroke, they found.
An alarming 94.2% of people with stroke, nearly double the control group, had one or more additional morbidities. Among the stroke group, more than 12% had 11 or more repeat prescriptions as compared to only 1.5% of the control group.
Those with multimorbidities and polypharmacy are easily over burdened by their treatment regimens, which can result in ineffective treatments and wasted resources. The results of the study should therefore have implications for both clinical guidelines and the health services offered to those experiencing multiple chronic illnesses.
People with Stroke More Likely to Have Multimorbidities
This study looks at the prevalence of multimorbidity (the presence of two or more long-term conditions) internationally. Multimorbidity affects patients by increasing their burden of symptoms, but is also likely to increase the self-care demands, or treatment burden, that they experience.
Treatment burden refers to the effort expended in operationalising treatments, navigating healthcare systems and managing relations with healthcare providers. These risks rise sharply in people diagnosed with chronic illness such as stroke.
Katie I. Gallacher, of the University of Glasgow in Scotland, and colleagues, examined the prevalence of multimorbidity and polypharmacy in a large, nationally representative population of primary care patients with and without stroke, adjusting for age, sex and deprivation.
Next Article in Stroke
Neurology Advisor Articles
- US Opioid Overdose Deaths Reach Record Number
- Migraine Treatment in the ED: Overcoming Our Penchant for Opioids
- Abnormalities in Genes Linked to IRSP in Alzheimer Disease
- Erenumab as a Therapy for Hard to Treat Episodic Migraine
- Recommended Levels of Cardiovascular Risk Factors Associated With Cerebral Vessel Density, Flow
- New Diagnostic Criteria for Neurosarcoidosis: What You Need to Know
- Guideline for Diagnosis and Treatment of Idiopathic Intracranial Hypertension
- Guidelines on the Use of OnabotulinumtoxinA for Chronic Migraine
- Ivy League Rule Change Linked to Fewer Concussions During NCAA Football Games
- Addressing Levodopa-Resistant Parkinson Disease
- Cannabidiol Gets Orphan Drug Status for Preventing Ischemia-Reperfusion Injury
- Early Clinical Predictors of Mortality in Parkinson Disease, Parkinsonism
- Lasmiditan NDA Submitted for Acute Treatment of Migraine
- HHS: Updated Physical Activity Guidelines for Americans Released
- 18F-FDG PET Algorithm Allows Early Prediction of Alzheimer's